Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)
Sponsor: Merck Sharp & Dohme LLC
Summary
Researchers are looking for new ways to treat people with B-cell cancers. In this trial, researchers will look at chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). These are blood cancers that affect B-cells in the blood, bone marrow, or lymph nodes. The goals of this trial are to learn about: * The safety of MK-1045 and if participants tolerate it. Tolerate means participants will receive trial treatment unless they need to stop treatment due to health problems. * The number of participants who respond. Respond means the number of cancer cells goes down or signs of cancer go away.
Official title: A Phase 2, Open-label, Multicenter Study to Determine the Safety, Tolerability, and Efficacy of MK-1045 in Participants With Hematologic Malignancies
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2026-08-21
Completion Date
2033-11-16
Last Updated
2026-07-16
Healthy Volunteers
No
Interventions
MK-1045
Intravenous (IV) infusion
Acetaminophen (or similar antipyretic)
Oral administration as a premedication
Diphenhydramine (or similar antihistamine)
Per approved product label as a premedication
Dexamethasone
IV administration as a premedication
Tocilizumab
IV administration as a rescue medication
Tocilizumab biosimilar
IV administration as a rescue medication
Siltuximab
IV administration as a rescue medication